Ideaya Biosciences Inc (IDYA)

Hedge Alert Live - Protect Your Portfolio Contract: $IDYA $30.00 Put · NOV 21, 2025 Exp Entry Price: $1.00 - $1.00 Exit Price Target: $2.27 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

$MDGL $ARGX $IDYA reduced these a bit. 55% cash now

$IDYA Still a dead board. Most bullish indicator in biotech.

Hedge Alert Live - Protect Your Portfolio Contract: $IDYA $30.00 Put · NOV 21, 2025 Exp Entry Price: $1.00 - $1.00 Exit Price Target: $1.34 Profit Margin: +34% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA April 17, 2026 $35 Calls Scale in: $5.56- $6.79 Scale out: $21.61-$37.05 Profit Potential : 118% ROI Blended Join 💎 Here: https://liquidtheta.com

$IDYA: The current market context shows a last close at $31.82, with an RSI of 62.45 indicating bullish momentum but approaching overbought territory. The 30-day moving average (MA30) at $29.55 and the 50-day moving average (MA50) at $28.01 suggest a strong upward trend, as the price is significantly above these averages. The 60-day high of $33.64 presents a potential resistance level, while the 60-day low of $23.23 indicates a solid support base. Directional bias is bullish due to the price being above both MAs and the RSI indicating strength, although caution is warranted as the RSI approaches overbought levels. Suggested entry: $32.00, with a stop loss at $30.50 to manage risk. Target 1: $33.00 (near the 60D high), Target 2: $34.00 (psychological resistance). Monitor for potential reversal signals if the price approaches the high. https://privateprofiteers.com

$IDYA: The last close at $32.01 indicates a strong position within the recent trading range, with a 60D high of $33.64 and a low of $23.23. The RSI at 64.79 suggests that the stock is nearing overbought territory, which may indicate a potential pullback. However, the stock is above both the 30-day MA (29.24) and the 50-day MA (27.77), indicating a bullish trend. Directional bias: Bullish, but cautious due to the elevated RSI. Suggested entry: Consider entering on a pullback to around $31.00, where there is potential support. Stop: Place a stop loss at $29.50 to limit downside risk. Targets: Set the first target at $33.00, just below the 60D high, and a second target at $34.00, allowing for further upside if momentum continues. Monitor for any changes in market sentiment that could affect price action. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA April 17, 2026 $35 Calls Scale in: $5.42- $6.63 Scale out: $21.09-$36.15 Profit Potential : 349% ROI Blended Join 💎 Here: https://liquidtheta.com

$IDYA: The last close at $32.01 indicates a strong position within the recent trading range, with a 60D high of $33.64 and a low of $23.23. The RSI at 64.79 suggests that the stock is nearing overbought territory, which may indicate a potential pullback. However, the stock is above both the 30-day MA (29.24) and the 50-day MA (27.77), indicating a bullish trend. Directional bias: Bullish, but cautious due to the elevated RSI. Suggested entry: Consider entering on a pullback to around $31.00, where there is potential support. Stop: Place a stop loss at $29.50 to limit downside risk. Targets: Set the first target at $33.00, just below the 60D high, and a second target at $34.00, allowing for further upside if momentum continues. Monitor for any changes in market sentiment that could affect price action. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA April 17, 2026 $35 Calls Scale in: $5.49- $6.71 Scale out: $21.35-$36.60 Profit Potential : 328% ROI Blended Join 💎 Here: https://liquidtheta.com

Mizuho has updated their rating for IDEAYA Biosciences ( $IDYA ) to Outperform with a price target of 46.

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA April 17, 2026 $35 Calls Scale in: $5.33- $6.52 Scale out: $20.74-$35.55 Profit Potential : 375% ROI Blended Join 💎 Here: https://liquidtheta.com

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA April 17, 2026 $35 Calls Scale in: $5.11- $6.24 Scale out: $19.86-$34.05 Profit Potential : 269% ROI Blended Join 💎 Here: https://liquidtheta.com

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $6.17- $7.54 Scale out: $23.97-$41.10 Profit Potential : 76% ROI Blended Join 💎 Here: https://liquidtheta.com

$IDYA Enough funds to operate to 2030. Entire pipeline undervalued at 1.5b. Where is the love.

💎 LiquidTheta® Options Alert Asset: $IDYA Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $6.41- $7.84 Scale out: $24.94-$42.75 Profit Potential : 310% ROI Blended Join 💎 Here: https://liquidtheta.com

$IDYA 🤔🤔🤔

$IDYA love this flex ~$1.14 billion of cash, cash equivalents, and marketable securities as of September 30, 2025; expected to fund operations into 2030

$IDYA Silent bleeding. Ready to add more in higher 20s if needed.

$IDYA IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end 21.1 month median OS and 7.0 month median PFS reported from single-arm Phase 2 trial (OptimUM-01) evaluating the darovasertib/crizotinib combination in 1L mUM Phase 1 data reported in SCLC for IDE849 (DLL3 TOP1i ADC) at the World Conference on Lung Cancer. Preliminary evidence of clinical efficacy was also observed in NETs patients, including Partial Responses by RECIST 1.1 Go-forward dose selected for IDE397 and Trodelvy® clinical combination in MTAP-deleted urothelial cancer (UC), and FPI achieved in non-small cell lung cancer (NSCLC); next clinical update planned for a medical conference in the first half of 2026 IND clearance for IDE892 (PRMT5) received in 3Q 2025; IND filing for IDE034 (B7H3/PTK7 bispecific TOP1i ADC) complete, with IND filing for IDE574 (KAT6/7) on track for year-end 2025 Entered into an exclusive license agreement with Servier for rights to darovasertib outside the United States; IDEAYA received $210 million upfront and is eligible for up to $320 million in milestone payments $1.14 billion of cash, cash equivalents, and marketable securities as of September 30, 2025; expected to fund operations into 2030

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $31.38 Contracts: $IDYA April 17, 2026 $35 Calls Scale in: $6.30- $7.70 Scale out: $9.80-$12.60 Can Easily Capture: 60% ROI Blended DTE: 165 Days | Join Elites here: https://liquidtheta.com

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $31.86 Contracts: $IDYA April 17, 2026 $35 Calls Scale in: $6.19- $7.56 Scale out: $9.62-$12.38 Can Easily Capture: 60% ROI Blended DTE: 166 Days | Join Elites here: https://liquidtheta.com